Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
3 raisons identifiées
Plateau technique de référence
Assistance publique – Hôpitaux de Paris (APHP) — équipements et expertise pointus pour les cas complexes
Auteur de référence en rhumatologie
28 articles scientifiques publiés — un praticien à la pointe de la recherche
Délais de RDV courts dans la région
336.2 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Influence scientifique
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
41
41 articles ont été cités au moins 41fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
h-index
Total citations reçues
10 467
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
234
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
90
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Affiliations FR : Sorbonne Université · Assistance Publique – Hôpitaux de Paris · Groupe Hospitalier Cochin - Port-Royal, Hôtel-Dieu, Broca - La Collégiale
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
TNF Inhibitor‐Induced Sarcoidosis‐Like Lesions in Inflammatory Bowel Disease
2025ArticleUnited European Gastroenterology Journal
Vaccines and the risk of Guillain-Barré syndrome: A French pharmacovigilance analysis
2025ArticleTherapies
Prescribing and Dispensing of Oral Isotretinoin and Noncompliance with Recommendations in France before and during the COVID‐19 Pandemic
2025ArticleDermatology and Therapy
Diagnosing and Managing Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis in Adults: Review of Evidence 2017–2023
2025ArticleJournal of Investigative Dermatology
Recurrences and rechallenges of suspected drugs in patients with epidermal necrolysis
2025ArticleClinical and Experimental Dermatology
Real-life prognosis of neurological complications of botulinum toxin: A nationwide pharmacovigilance study of adverse drug reactions reported in France between 1994 and 2020
2025ArticleAnnals of Physical and Rehabilitation Medicine
Incidence, In-Hospital and Long-Term Mortality, and Sequelae of Epidermal Necrolysis in Adults
2024ArticleJAMA Dermatology
Comparison of incidence, causes and prognosis of adult and paediatric epidermal necrolysis: a French population-based study
2024ArticleBritish Journal of Dermatology
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
GHU APHP SUN SITE PITIE SALPETRIERE
47-83 47 BD DE L HOPITAL, 75651 PARIS CEDEX 13
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Nature communications · 2022
AbstractWhile multiple pharmacological drugs have been associated with myocarditis, temporal trends and overall mortality have not been reported. Here we report the spectrum and main features of 5108 reports of drug-induced myocarditis, in a worldwide pharmacovigilance analysis, comprising more than 21 million individual-case-safety reports from 1967 to 2020. Significant association between myocarditis and a suspected drug is assessed using disproportionality analyses, which use Bayesian information component estimates. Overall, we identify 62 drugs associated with myocarditis, 41 of which are categorized into 5 main pharmacological classes: antipsychotics (n = 3108 reports), salicylates (n = 340), antineoplastic-cytotoxics (n = 190), antineoplastic-immunotherapies (n = 538), and vaccines (n = 790). Thirty-eight (61.3%) drugs were not previously reported associated with myocarditis. Antipsychotic was the first (1979) and most reported class (n = 3018). In 2019, the two most reported classes were antipsychotics (54.7%) and immunotherapies (29.5%). Time-to-onset between treatment start and myocarditis is 15 [interquartile range: 10; 23] days. Subsequent mortality is 10.3% and differs between drug classes with immunotherapies the highest, 32.5% and salicylates the lowest, 2.6%. These elements highlight the diversity of presentations of myocarditis depending on drug class, and show the emerging role of antineoplastic drugs in the field of drug-induced myocarditis.
JAMA dermatology · 2024
ImportanceDrug reaction with eosinophilia and systemic symptoms (DRESS) is a rare but potentially fatal drug hypersensitivity reaction. To our knowledge, there is no international consensus on its severity assessment and treatment.ObjectiveTo reach an international, Delphi-based multinational expert consensus on the diagnostic workup, severity assessment, and treatment of patients with DRESS.Design, Setting, and ParticipantsThe Delphi method was used to assess 100 statements related to baseline workup, evaluation of severity, acute phase, and postacute management of DRESS. Fifty-seven international experts in DRESS were invited, and 54 participated in the survey, which took place from July to September 2022.Main Outcomes/MeasuresThe degree of agreement was calculated with the RAND-UCLA Appropriateness Method. Consensus was defined as a statement with a median appropriateness value of 7 or higher (appropriate) and a disagreement index of lower than 1.ResultsIn the first Delphi round, consensus was reached on 82 statements. Thirteen statements were revised and assessed in a second round. A consensus was reached for 93 statements overall. The experts agreed on a set of basic diagnostic workup procedures as well as severity- and organ-specific further investigations. They reached a consensus on severity assessment (mild, moderate, and severe) based on the extent of liver, kidney, and blood involvement and the damage of other organs. The panel agreed on the main lines of DRESS management according to these severity grades. General recommendations were generated on the postacute phase follow-up of patients with DRESS and the allergological workup.Conclusions and RelevanceThis Delphi exercise represents, to our knowledge, the first international expert consensus on diagnostic workup, severity assessment, and management of DRESS. This should support clinicians in the diagnosis and management of DRESS and constitute the basis for development of future guidelines.
British journal of clinical pharmacology · 2023
AimsIn the last French study in 2007, the incidence of hospital admissions (HAs) related to adverse drug reactions (ADRs) was 3.6%. The objective was to assess the current ADR‐HA incidence in France and to describe both its characteristics and preventability.MethodsA prospective multicentre study was conducted among randomly selected French public hospital medical wards (April–July 2018). Patients admitted during a week period were included. ADR‐HA cases were collected by the French Regional Pharmacovigilance Centres network. An independent committee validated potential cases and ADR preventability.ResultsADR‐HA incidence was 8.5% (95% confidence interval [CI]: 7.6–9.4%), increasing with age (3.3% [95%CI: 1.8–5.5%] ≤16 y vs. 10.6% [95%CI: 9.3–12.0%] ≥65 y). The most common ADRs were haemorrhagic events (8.8%), haematological disorders (6.5%), acute renal failure (6.3%), fluid and electrolyte disorders (6.0%), and falls (5.2%). New drugs were involved: targeted therapies (22.8% of antineoplastics), direct oral anticoagulants (29.6% of antithrombotics) and incretin‐based drugs (20.0% of antidiabetics). ADRs were preventable in 16.1% of cases because the drugs involved had not been used in accordance with monographies, package leaflets or other therapeutic guidelines. The main situations of noncompliance addressed either dose or duration of use (27.9%), warning (23.2%), use precaution (18.6%) and inappropriate self‐medication or misuse by patients (11.6%).ConclusionIn France, ADR‐HA incidence dramatically increased over the last decade. A significant proportion was related to new pharmacological classes and considered as preventable. These findings should lead to in‐depth thought on preventive actions on at‐risk drug classes.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
United European gastroenterology journal · 2026 · Journal Article
Chkolnaia Z, Lebrun-Vignes B, Amiot A, Uzzan M, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV · 2025 · Letter
Thorn A, Lebrun Vignes B, Welfringer-Morin A, Lebret J, et al.
Therapie · 2025 · Letter
Ingen-Housz-Oro S, Sanchez-Pena P, Lebrun-Vignes B, Bihan K, et al.
Therapie · 2025 · Journal Article
Gligorov M, Lebrun-Vignes B, Masmoudi K, Vial T, et al.
Annals of physical and rehabilitation medicine · 2025 · Journal Article
Carpentier VT, Weiss N, Salem JE, Joussain C, et al.
BMC pulmonary medicine · 2024 · Journal Article
Brudon A, Fournier D, Selle F, Seront E, et al.
Therapie · 2024 · Journal Article
Bettuzzi T, Sanchez-Pena P, Lebrun-Vignes B
Therapie · 2023 · Observational Study
Demouche S, Bettuzzi T, Sbidian E, Laugier Castellan D, et al.
Melanoma research · 2023 · Journal Article
Ingen-Housz-Oro S, Milpied B, Bensaid B, Elshot Y, et al.
The Journal of infection · 2023 · Letter
Chouchana L, Fournier D, Lebrun-Vignes B, Florence S, et al.
Journal of neurology · 2023 · Journal Article
Balcerac A, Bihan K, Psimaras D, Lebrun-Vignes B, et al.
Therapie · 2023 · Journal Article
Deplanque D, Fetro C, Ferry A, Lechat P, et al.
Therapie · 2023 · Journal Article
Deplanque D, Fetro C, Ferry A, Lechat P, et al.
The journal of allergy and clinical immunology. In practice · 2022 · Multicenter Study
Roux C, Ben Said B, Milpied B, Bernier C, et al.
The British journal of dermatology · 2022 · Letter
Darrigade AS, Oulès B, Sohier P, Jullie ML, et al.
Journal of neurology · 2022 · Letter
Jeantin L, Hesters A, Fournier D, Lebrun-Vignes B, et al.
Annals of intensive care · 2022 · Journal Article
Balcerac A, Bihan K, Lebrun-Vignes B, Thabut D, et al.
Therapie · 2022 · Case Reports
Braesch C, Weill A, Gaudin O, Lebrun-Vignes B, et al.
Nature communications · 2022 · Journal Article
Nguyen LS, Cooper LT, Kerneis M, Funck-Brentano C, et al.
JAMA dermatology · 2024 · Journal Article
Bettuzzi T, Lebrun-Vignes B, Ingen-Housz-Oro S, Sbidian E
The British journal of dermatology · 2024 · Journal Article
Bettuzzi T, Welfringer-Morin A, Ingen-Housz-Oro S, Bataille P, et al.
British journal of clinical pharmacology · 2023 · Observational Study
The British journal of dermatology · 2024 · Journal Article
Bettuzzi T, Welfringer-Morin A, Ingen-Housz-Oro S, Bataille P, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV · 2024 · Journal Article
Bataille P, Lebrun-Vignes B, Bettuzzi T, Ingen-Housz-Oro S, et al.
Annales de dermatologie et de venereologie · 2026 · Journal Article
Ribereau-Gayon E, Lesort C, Bienvenu FH, Mathian A, et al.
Pharmacoepidemiology and drug safety · 2022 · Journal Article
Bettuzzi T, Ingen-Housz-Oro S, Maison P, de Prost N, et al.
Annales de dermatologie et de venereologie · 2026 · Journal Article
Ribereau-Gayon E, Lesort C, Bienvenu FH, Mathian A, et al.
JAMA dermatology · 2022 · Journal Article
Bataille P, Lebrun-Vignes B, Tubach F, Aroux-Pavard M, et al.
JAMA dermatology · 2024 · Journal Article
Brüggen MC, Walsh S, Ameri MM, Anasiewicz N, et al.
Therapie · 2023 · English Abstract
Philibert C, Bres V, Jean-Pastor MJ, Guy C, et al.
Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study
Abstract Background Immune checkpoint inhibitors (ICI) produce durable antitumor responses but provoke autoimmune toxicities, including uncommon but potentially devastating neurologic toxicities. The clinical features, i
Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study
Abstract Background Immune checkpoint inhibitors (ICI) produce durable antitumor responses but provoke autoimmune toxicities, including uncommon but potentially devastating neurologic toxicities. The clinical features, i
Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).
Laroche ML, Gautier S, Polard E, Rabier MB, et al.